A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
about
Cytokine-Induced Modulation of Colorectal CancerInterleukin 12: still a promising candidate for tumor immunotherapy?HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primatesWay to go to exploit NK cells' versatile talents for cancer immunotherapy.A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.New insights into IL-12-mediated tumor suppression.NK cell-based immunotherapy for treating cancer: will it be promising?New developments in the treatment of metastatic gastric cancer: focus on trastuzumabAbrogation of TNFα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12.Differential growth inhibition of cerebral metastases by anti-angiogenic compoundsA multiscale systems perspective on cancer, immunotherapy, and Interleukin-12Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signalingStimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12.Natural killer cells: role in local tumor growth and metastasisMonoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.Antiangiogenic therapies in early-stage breast cancer.Biological role of NK cells and immunotherapeutic approaches in breast cancer.IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.Sorafenib: where do we go from here?Promising systemic immunotherapies in head and neck squamous cell carcinoma.The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Combining immunotherapy and targeted therapies in cancer treatment.Combination strategies to enhance antitumor ADCC.Advances in biomarkers for esophageal cancer.Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.Emerging immunotherapy strategies in breast cancer.Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.Expression of interleukin-12 by adipose-derived mesenchymal stem cells for treatment of lung adenocarcinomaInterplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Harnessing the immune system in the battle against breast cancer.Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25.Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
P2860
Q26752374-8F79C7C9-DDF9-4E2A-9F1B-04A87D9D1E9EQ26861559-741BB1A2-60C4-46F6-A874-EBFEAD70EA9FQ28731776-F893202F-241B-4C62-9934-BD6D7E2812C9Q34302440-1E79F1EF-453F-4CE0-822A-71DAD0E88AC2Q34331673-4DD7F535-9D6F-4EC9-8BC2-E6D46F688AFDQ34436897-84717751-EF2B-495B-8C02-730009804DF1Q34729280-06496412-C6AA-416D-AA7E-2A5C7439AA1DQ34883258-39767E8C-7E45-4C95-8093-D4FF0F921EC8Q35108695-B9E4E20C-9221-4429-BC83-AF2083AE6C33Q35304863-83D0E421-75BC-4012-9503-E76E9AD87F74Q35624686-7628837F-2883-4206-936A-6FCFA57C069EQ35779345-3EB609C7-6EE6-4CA4-B5DD-575C9750FC69Q35780315-0D87E202-C456-4862-A9E5-2FE183DE1D92Q35809223-D0B128C9-F8FC-4D4C-ADC7-D0768F26540FQ35905953-3D76CD4D-CF36-46AA-BC18-2BA5AEFDD5F2Q35962555-CA40DCE4-6ECA-486B-ABB8-276E60B1F175Q36109555-961DDED3-C4BF-4A01-B1D2-3AFAA41C5DF0Q36204962-0C11E91D-F584-4E53-9966-4B084E5FD3DFQ36318210-C2E49723-DAC4-47C5-80B2-ECEFCC537132Q36460884-BB4C8AEF-369B-486C-95D7-19C68ADECD07Q36671364-580D0F12-399A-4A5D-A743-567F3F22CCE2Q36708741-86C872EB-D14E-424F-A817-C4C604211883Q36883848-4E4C7C01-A6B3-457B-BF31-CCBFCBAAD1B8Q37413162-0B00A6C2-7E69-406A-85A0-D00435531F3DQ37995939-28B4D110-75B0-491E-AB55-79EE3F3D0840Q38014085-D1351F28-AF71-4BD4-ACD2-5341F981BA9DQ38153443-E761835A-09B3-49F6-8D48-35B06F724347Q38162129-95C1BC67-8E06-483D-BBA8-36F0B158F301Q38184650-D9EA929B-2EDA-4EF1-B74E-60D560A7B4B9Q38412375-1A6A2AA3-307A-424D-9133-2FA0D02658A4Q38703318-3E1F3E05-45E6-447E-BAF0-823A4B8C329FQ39231967-3A075295-B844-4973-BDAD-E49BCB427FFAQ40642974-C2A71D62-8BDA-457C-9D97-2FF9731F0AF0Q41340974-7998F133-196C-4BF4-9C1A-8012851FD9CCQ47156322-16B72A45-7131-44FA-8680-D4BEE1393AEDQ49884762-36EB7959-E224-424C-BE21-D0A4A0882047Q50545440-B38F64E4-5079-4E93-8C29-5EA395C487CFQ54594739-A09D0EA8-51A4-495C-A788-24BB68F346B0
P2860
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@ast
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@en
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@nl
type
label
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@ast
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@en
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@nl
prefLabel
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@ast
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@en
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@nl
P2093
P2860
P921
P1476
A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.
@en
P2093
Amy K Ferketich
Bhuvanaswari Ramaswamy
Charles L Shapiro
Donn C Young
Kristan D Guenterberg
Michael R Grever
Tammy A Lamb
Tanios S Bekaii-Saab
William E Carson
P2860
P304
P356
10.1158/1535-7163.MCT-09-0820
P50
P577
2009-11-03T00:00:00Z